ORION CORP. 271560

ORION CORPORATION STOCK EXCHANGE RELEASE – OTHER INFORMATION DISCLOSED ACCORDING TO THE RULES OF THE EXCHANGE30 SEPTEMBER 2026 at 9.05 EEST Orion Corporation completed share acquisitions The share acquisitions announced by Orion Corporation on 27 August 2026 have been completed. The Company has purchased during the time period from 1 September 2026 to 29 September 2026 through trading on regulated market organised by Nasdaq Helsinki Oy a total of 500,000 Company's own B shares at an average pric

ORION CORPORATION STOCK EXCHANGE RELEASE – CHANGES IN COMPANY’S OWN SHARES30/09/2026 at 09.00 EEST Orion Corporation: Acquisition of own shares during week 40, 2026 The share buybacks form part of the share buyback programme that Orion Corporation announced on 27 August 2026. The buyback programme runs from 1 September 2026 until no later than 31 December 2026, and it is executed in compliance with Regulation No. 596/2014 of the European Parliament and Council (MAR) Article 5 and the Commission

Orion Corporation: Acquisition of own shares during week 39, 2026 The share buybacks form part of the share buyback programme that Orion Corporation announced on 27 August 2026. The buyback programme runs from 1 September 2026 until no later than 31 December 2026, and it is executed in compliance with Regulation No. 596/2014 of the European Parliament and Council (MAR) Article 5 and the Commission Delegated Regulation (EU) 2016/1052. Orion Corporation’s shares have been acquired as follows: Date

ORION CORPORATION STOCK EXCHANGE RELEASE – CHANGES IN COMPANY’S OWN SHARES18/09/2026 at 19.00 EEST Orion Corporation: Acquisition of own shares during week 38, 2026 The share buybacks form part of the share buyback programme that Orion Corporation announced on 27 August 2026. The buyback programme runs from 1 September 2026 until no later than 31 December 2026, and it is executed in compliance with Regulation No. 596/2014 of the European Parliament and Council (MAR) Article 5 and the Commission

Orion Corporation: Acquisition of own shares during week 37, 2026 The share buybacks form part of the share buyback programme that Orion Corporation announced on 27 August 2026. The buyback programme runs from 1 September 2026 until no later than 31 December 2026, and it is executed in compliance with Regulation No. 596/2014 of the European Parliament and Council (MAR) Article 5 and the Commission Delegated Regulation (EU) 2016/1052. Orion Corporation’s shares have been acquired as follows: Date

ORION CORPORATION STOCK EXCHANGE RELEASE – CHANGES IN COMPANY’S OWN SHARES4 September 2026 at 19.00 EEST Orion Corporation: Acquisition of own shares during week 36, 2026 The share buybacks form part of the share buyback programme that Orion Corporation announced on 27 August 2026. The buyback programme runs from 1 September 2026 until no later than 31 December 2026, and it is executed in compliance with Regulation No. 596/2014 of the European Parliament and Council (MAR) Article 5 and the Commi

ORION CORPORATION STOCK EXCHANGE RELEASE – OTHER INFORMATION DISCLOSED ACCORDING TO THE RULES OF THE EXCHANGE 4 SEPTEMBER 2026 at 9.00 EEST 102,000 Orion Corporation A shares converted into B shares In accordance with Section 3 of the Articles of Association of Orion Corporation, 102,000 A shares have been converted into 102,000 B shares. The conversion has been entered into the Trade Register on 4 September 2026. The total number of shares in Orion Corporation is 141,134,278 which, after the co

ORION CORPORATION STOCK EXCHANGE RELEASE – OTHER INFORMATION DISCLOSED ACCORDING TO THE RULES OF THE EXCHANGE27 AUGUST 2026 at 13.00 EEST Orion Corporation to commence acquisition of own shares for its share-based incentive plans On 27 August 2026, the Board of Directors of Orion Corporation decided to commence acquisition of the Company’s own shares based on the authorisation granted by the Annual General Meeting held on 24 March 2026. According to the decision, up to 500,000 Class B shares of

ORION CORPORATION HALF-YEAR FINANCIAL REPORT 1–6/2026 17 JULY 2026 at 12:00 EEST Orion Group Half-Year Financial Report January–June 2026 April–June 2026 Highlights Net sales totalled EUR 521.6 (April–June 2025: 416.5) million Operating profit was EUR 176.6 (104.6) millionBasic earnings per share were EUR 1.00 (0.59)Cash flow from operating activities per share was EUR 1.95 (0.57)Several key milestones reached with ODM-212 development assetFDA approval for Animal Health division's Tessie® Januar

ORION CORPORATION STOCK EXCHANGE RELEASE – FINANCIAL CALENDAR 17 JULY 2026 at 10.30 EEST Orion Corporation’s financial reporting and Annual General Meeting in 2027 Orion Corporation will publish its Financial Statement Release 2026 on Wednesday, 17 February 2027. The Financial Statements and the Report by the Board of Directors for 2026 will be published at the latest in week 9/2027. The publication dates of the Interim Reports and the Half-Year Financial Report in 2027 are as follows: Interim R

ORION CORPORATION STOCK EXCHANGE RELEASE – OTHER INFORMATION DISCLOSED ACCORDING TO THE RULES OF THE EXCHANGE 15 JULY 2026 at 9.00 EEST 45,611 Orion Corporation A shares converted into B shares In accordance with Section 3 of the Articles of Association of Orion Corporation, 45,611 A shares have been converted into 45,611 B shares. The conversion has been entered into the Trade Register on 15 July 2026. The total number of shares in Orion Corporation is 141,134,278 which, after the conversion, c

DHARWAD, India, July 06, 2026--Shilpa Medicare and Orion Corporation expand partnership to develop and supply intravenous nivolumab biosimilar to widen patient access across Europe.

ORION CORPORATION PRESS RELEASE 3 JULY 2026 at 9.00 EEST Orion publishes Half-Year Report for January–June 2026 and holds a webcast on 17 July 2026 Orion will publish Half-Year Report for January–June 2026 on Friday, 17 July 2026 at approximately 12.00 noon EEST. The report and related presentation material will be available on the company’s website at www.orionpharma.com/investors after publishing. Webcast and conference call A webcast and a conference call for analysts, investors and media rep

ORION CORPORATION PRESS RELEASE 30 JUNE 2026 at 8.00 EEST Orion Pharma announces agreement with Shilpa Medicare for nivolumab biosimilar for European market Orion Pharma (“Orion”) and Shilpa Biologicals Private Limited, a fully-owned subsidiary of Shilpa Medicare Limited (“Shilpa”), have entered into an agreement to commercialise intravenous (iv) nivolumab biosimilar in Europe. Nivolumab is an immune checkpoint inhibitor which is used to treat various cancers. Shilpa’s nivolumab biosimilar is cu

ORION CORPORATION PRESS RELEASE 23 JUNE 2026 at 9:30 EEST Orion Pharma’s ODM-212 Granted Orphan Designation for the Treatment of Malignant Mesothelioma by the European Commission Orion Corporation (Orion Pharma) today announced that its investigational drug ODM-212 has received Orphan Designation from the European Commission, based on the recommendation from the European Medicines Agency’s (EMA) Committee for Orphan Medicinal Products (COMP), for the treatment of malignant mesothelioma, which is